Board of Directors
Bobby is co-founder and CEO of Tarsus. He has co-founded and built three companies advancing pioneering chronic disease treatments; provided leadership and strategic guidance through discovery, development, and commercialization; and has led several successful fundraising efforts, including the Tarsus initial public offering. Bobby previously served as CEO and Chief Medical Officer of Metavention. He also serves on the boards of Vibrato Medical and the nonprofit Octane.
Bobby began his biotechnology career as an investor and entrepreneur with Versant Ventures and Third Rock Ventures. He previously completed a residency in internal medicine and was an attending hospitalist at Brigham and Women’s Hospital. He received an M.D. from Harvard Medical School (Harvard-MIT Health Sciences and Technology), a Ph.D. in chemistry from Oxford University as a Rhodes Scholar, and a B.A. in physics from Rice University.
Michael is a co-founder and Chairman of the Board of Tarsus. He is also co-founder, CEO and serves on the board of Presidio Medical. He formerly served as Chairman of Oyster Point Pharma, Inc. (NASDAQ: OYST). He was also previously Vice President, Neurostimulation for Allergan (an AbbVie company) after serving as CEO of Oculeve, Inc., which was acquired by Allergan. He received a B.E. degree in biomedical engineering from Vanderbilt University and M.S. and Ph.D. degrees in biomedical engineering from Case Western Reserve University. He is a graduate of Stanford University’s Biodesign Fellowship and Vision Research Fellowship. He has numerous patents and peer-reviewed publications.
Bhaskar is Operating Partner at Frazier Healthcare Partners where he joined in 2011 and brings to the Life Sciences team significant operational experience in drug research, development, and commercialization in the United States, Europe, and emerging markets. He leads investments in later-stage companies and in international opportunities and is a co-founder of Arcutis (NASDAQ: ARQT), where he currently serves on the Board. Bhaskar also serves on the Board of Teligent (NASDAQ: TLGT) and is an advisor to the Johns Hopkins Berman Institute of Bioethics. Bhaskar also served on the board of directors of Silvergate Pharmaceuticals (acquired by CutisPharma), Corium International (acquired by Gurnet Point Capital) and Thesan Pharmaceuticals.
Prior to joining Frazier, Bhaskar was President of Valeant Pharmaceuticals, where he led Valeant’s international operations and business development activities. He joined Valeant through its acquisition of Dow Pharmaceutical Sciences, where he had been President and CEO. Before Dow, Bhaskar worked at Mylan Pharmaceuticals in several capacities including EVP of Scientific Affairs at Mylan subsidiary Bertek Pharmaceuticals, and as General Manager of the Dermatology Division. Earlier, he worked at Penederm, a skin-products and drug-delivery company, as VP of R&D.
Bhaskar holds a Ph.D. in Pharmaceutics, a M.S. in Industrial Pharmacy and a B.S. in Pharmacy.
Dr. Goldberg is a U.S. board-certified physician in both Critical Care Medicine and Emergency Medicine. He served as an Instructor in Medicine at the Mayo Clinic College of Medicine in Rochester, MN, where he completed a fellowship in Critical Care Medicine and served as an Attending Physician in the Department of Emergency Medicine. Prior to this, he completed Emergency Medicine residency training at Los Angeles County + University of Southern California Medical Center (LAC+USC).
Dr. Goldberg received his M.D. from The George Washington University School of Medicine in Washington, DC, and has held academic and clinical appointments at the Stanford VA Palo Alto Medical Center, Oregon Health & Science University, the University of Arizona, and currently at the Washington Township Medical Foundation.
Bill is Founder and Managing Partner of Flying L Partners and a Founder and Managing Director of Versant Ventures. He specializes in early-stage investing in medical devices. Prior to co-founding Versant Ventures, Bill was a general partner at Brentwood Venture Capital and has over two decades of operations experience in the healthcare industry. Bill was previously Founder, Chairman, and CEO of Chiron Vision, which was sold to Bausch and Lomb in 1997. Prior to Chiron Vision, Bill founded and served as President of American Medical Optics (AMO), a division of American Hospital Supply Corporation, which was sold to Allergan in 1986. Later, he served on the Board of AMO’s successor company, Advanced Medical Optics (AMO) which was acquired by Abbott in 2009 and then by Johnson and Johnson in 2016. Before entering the healthcare industry, he was an Assistant Professor in the Department of Surgery at the Indiana University School of Medicine. Bill currently serves on the board of several private companies and Edwards Lifesciences (NYSE: EW), Glaukos (NYSE: GKOS), and Oyster Point Pharma, Inc. (NASDAQ: OYST). He received his B.S., M.S., and Ph.D. from Purdue University.
Jason is the Chief Financial Officer of the Horowitz Group, an opportunistic, multi-asset class family investment office in Newport Beach, California. Notable transactions include the ownership and sale of Standard Concrete and founding investments in Sprouts Farmers Markets and Lemonade, a fast-casual dining concept. In addition to CFO responsibilities, Jason is active in the firm’s healthcare transactions. Recent healthcare investments include Metavention, a medical device company developing a novel glucose control therapy for patients with Type 2 diabetes, and Tarsus Pharmaceuticals. Prior to Horowitz Group, Jason served for nine years as the CFO of AcuFocus, an ophthalmic medical device company focused on solutions for presbyopia. Previously, Jason worked in investment banking at Jefferies and BNP Paribas, with a concentration in healthcare and also worked in business development for the Innovation Factory, a medical device incubator. Jason began his career as a CPA; he holds an MBA from Emory University, a Master of Accountancy specializing in Tax, and a Bachelor’s in Business Administration from the University of Georgia. Jason is married with three children and serves on the Board and as Treasurer of Mariners Christian School.
Wendy has more than 30 years of experience in the biopharmaceutical industry, as a public company director and product commercialization leader, including 26 years at Merck & Co. Inc.
While at Merck, Wendy held positions of increasing seniority, most recently as Chief Marketing Officer. In that position, she led a global organization charged with all aspects of commercialization of pharmaceuticals in more than 20 therapeutic areas. She also served as General Manager, Cardiovascular/Metabolic U.S. Business Unit, and as Merck’s Senior Vice President of Human Resources. Earlier in her career, she was Vice President of the Women’s Health Care franchise for Johnson & Johnson’s Ortho-McNeil Pharmaceutical subsidiary.
Wendy has served on the boards of several public and private biotechnology and medical device companies, including St. Jude Medical, Medivation, Alder Biopharmaceuticals, Aratana Therapeutics, and Myokardia. She currently serves on the boards of Global Blood Therapeutics, Ideaya Biosciences, and Inovio Pharmaceuticals. Wendy received a B.S. in business administration from Portland State University and an M.B.A. from Temple University, Fox School of Business.